Human Genetics

, Volume 116, Issue 5, pp 361–367

CTLA-4 polymorphisms and systemic lupus erythematosus (SLE): a meta-analysis

Original Investigation

Abstract

Several reports demonstrate association between variants of the cytotoxic T lymphocyte antigen-4 (CTLA-4) and autoimmune diseases. CTLA-4 may generate autoimmunity by immune dysregulation, making CTLA-4 an attractive candidate gene for systemic lupus erythematosus (SLE) susceptibility. Previous CTLA-4 association studies with SLE, however, have produced inconsistent results. We have performed a meta-analysis to better assess the purported associations. A total of 14 independent studies (to July 2004) testing association between one or more CTLA-4 polymorphisms and SLE were used in this analysis. We have compared allele and genotype frequencies at four polymorphic sites found in exon-1 (at +49), the promoter region (at −318 and −1722), and the 3′ untranslated region (3′UTR) (dinucleotide repeat). We have evaluated both fixed and random effect models, depending on the presence of between-study heterogeneity. The data demonstrate that the exon-1 +49 polymorphism is significantly associated with SLE susceptibility. The overall risk, measured by odds ratio (OR), for exon-1 +49 GG genotype is 1.287 [95% confidence interval (CI)=1.031–1.562, P=0.011]. Stratification by ethnicity indicates the exon–1 +49 GG genotype is associated with SLE, at least in Asians (OR=1.293, 95% CI=1.031–1.620, P=0.026). European-derived populations have an effect of similar magnitude (OR=1.268, 95% CI=0.860–1.870, P=0.230), though not significant. Similar trends are found in allele-specific risk estimates and disease association. The OR for the exon-1 +49 risk allele (G) in Asians is 1.246 (95% CI=1.057–1.469, P=0.009), while Europeans have no evidence of allelic association (OR=0.978, 95% CI=0.833–1.148, P=0.780). In conclusion, this meta-analysis supports the CTLA-4 exon-1 +49 (A/G) polymorphism influencing the risk for developing SLE, especially in Asians.

References

  1. Aguilar F, Torres B, Sanchez-Roman J, Nunez-Roldan A, Gonzalez-Escribano MF (2003) CTLA4 polymorphism in Spanish patients with systemic lupus erythematosus. Hum Immunol 64:936–940CrossRefGoogle Scholar
  2. Ahmed S, Ihara K, Kanemitsu S, Nakashima H, Otsuka T, Tsuzaka K, Takeuchi T, Hara T (2001) Association of CTLA-4 but not CD28 gene polymorphisms with systemic lupus erythematosus in the Japanese population. Rheumatology (Oxford) 40:662–667Google Scholar
  3. Anjos S, Nguyen A, Ounissi-Benkalha H, Tessier MC, Polychronakos C (2002) A common autoimmunity predisposing signal peptide variant of the cytotoxic T-lymphocyte antigen 4 results in inefficient glycosylation of the susceptibility allele. J Biol Chem 277:6478–6486CrossRefGoogle Scholar
  4. Barreto M, Santos E, Ferreira R, Fesel C, Fontes MF, Pereira C, Martins B, Andreia R, Viana JF, Crespo F, Vasconcelos C, Ferreira C, Vicente AM (2004) Evidence for CTLA4 as a susceptibility gene for systemic lupus erythematosus. Eur J Hum Genet 12:620–626CrossRefGoogle Scholar
  5. Brunner MC, Chambers CA, Chan FK, Hanke J, Winoto A, Allison JP (1999) CTLA-4-Mediated inhibition of early events of T cell proliferation. J Immunol 162:5813–5820Google Scholar
  6. Chambers CA, Sullivan TJ, Allison JP (1997) Lymphoproliferation in CTLA-4-deficient mice is mediated by costimulation-dependent activation of CD4+ T cells. Immunity 7:885–895CrossRefGoogle Scholar
  7. Cochran WG (1954) The combination of estimates from different experiments. Biometrics 10:101–129Google Scholar
  8. Colhoun HM, McKeigue PM, Davey Smith G (2003) Problems of reporting genetic associations with complex outcomes. Lancet 361:65–72CrossRefGoogle Scholar
  9. D’Alfonso S, Rampi M, Bocchio D, Colombo G, Scorza-Smeraldi R, Momigliano-Rishardi P (2000) Systemic lupus erythematosus candidate genes in the Italian population: evidence for a significant association with interleukin-10. Arthritis Rheum 43:120–128CrossRefPubMedGoogle Scholar
  10. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177–188CrossRefPubMedGoogle Scholar
  11. Egger M, Davey SG, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629–634PubMedGoogle Scholar
  12. Fernandez-Blanco L, Perez-Pampin E, Gomez-Reino JJ, Gonzalez A (2004) A CTLA-4 polymorphism associated with susceptibility to systemic lupus erythematosus. Arthritis Rheum 50:328–329CrossRefGoogle Scholar
  13. Finck BK, Linsley PS, Wofsy D (1994) Treatment of murine lupus with CTLA4Ig. Science 265:1225–1227PubMedGoogle Scholar
  14. Gaffney PM, Kearns GM, Shark KB, Ortmann WA, Selby SA, Malmgren ML, Rohlf KE, Ockenden TC, Messner RP, King RA, Rich SS, Behrens TW (1998) A genome-wide search for susceptibility genes in human systemic lupus erythematosus sib-pair families. Proc Natl Acad Sci USA 95:14875–14879CrossRefPubMedGoogle Scholar
  15. Greenwald RJ, Latchman YE, Sharpe AH (2002) Negative co-receptors on lymphocytes. Curr Opin Immunol 14:391–396CrossRefGoogle Scholar
  16. Gribben JG, Freeman GJ, Boussiotis VA, Rennert P, Jellis CL, Greenfield E, Barber M, Restivo VA Jr, Ke X, Gray GS (1995) CTLA4 mediates antigen-specific apoptosis of human T cells. Proc Natl Acad Sci USA 92:811–815Google Scholar
  17. Harley JB, Moser KL, Gaffney PM, Behrens TW (1998) The genetics of human systemic lupus erythematosus. Curr Opin Immunol 10:690–696CrossRefPubMedGoogle Scholar
  18. Heward JM, Allahabadia A, Carr-Smith J, Daykin J, Cockram CS, Gordon C, Barnett AH, Franklyn JA, Gough SC (1998) No evidence for allelic association of a human CTLA-4 promoter polymorphism with autoimmune thyroid disease in either population-based case-control or family-based studies. Clin Endocrinol (Oxf) 49:331–334CrossRefGoogle Scholar
  19. Heward J, Gordon C, Allahabadia A, Barnett AH, Franklyn JA, Gough SC (1999) The A-G polymorphism in exon 1 of the CTLA-4 gene is not associated with systemic lupus erythematosus. Ann Rheum Dis 58:193–195Google Scholar
  20. Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21: 1539–1558CrossRefPubMedGoogle Scholar
  21. Hudson LL, Rocca K, Song YW, Pandey JP (2002) CTLA-4 gene polymorphisms in systemic lupus erythematosus: a highly significant association with a determinant in the promoter region. Hum Genet 111:452–455CrossRefGoogle Scholar
  22. Kouki T, Sawai Y, Gardine CA, Fisfalen ME, Alegre ML, DeGroot LJ (2000) CTLA-4 gene polymorphism at position 49 in exon 1 reduces the inhibitory function of CTLA-4 and contributes to the pathogenesis of Graves’ disease. J Immunol 165: 606–611Google Scholar
  23. Kristiansen OP, Larsen ZM, Pociot F (2000) CTLA-4 in autoimmune diseases–a general susceptibility gene to autoimmunity?. Genes Immun 1:170–184CrossRefGoogle Scholar
  24. Lee YH, Kim YR, Ji JD, Sohn J, Song GG (2001) Polymorphisms of the CTLA-4 exon 1 and promoter gene in systemic lupus erythematosus. Lupus 10:601–605CrossRefGoogle Scholar
  25. Liu MF, Wang CR, Lin LC, Wu CR (2001) CTLA-4 gene polymorphism in promoter and exon-1 regions in Chinese patients with systemic lupus erythematosus. Lupus 10:647–649CrossRefGoogle Scholar
  26. Matsushita M, Tsuchiya N, Shiota M, Komata T, Matsuta K, Zama K, Oka T, Juji T, Yamane A, Tokunaga K (1999) Lack of a strong association of CTLA-4 exon 1 polymorphism with the susceptibility to rheumatoid arthritis and systemic lupus erythematosus in Japanese: an association study using a novel variation screening method. Tissue Antigens 54:578–584CrossRefGoogle Scholar
  27. Maurer M, Loserth S, Kolb-Maurer A, Ponath A, Wiese S, Kruse N, Rieckmann P (2002) A polymorphism in the human cytotoxic T-lymphocyte antigen 4 (CTLA4) gene (exon 1 +49) alters T-cell activation. Immunogenetics 54:1–8CrossRefGoogle Scholar
  28. Mehrian R, Quismorio FP Jr, Strassmann G, Stimmler MM, Horwitz DA, Kitridou RC, Gauderman WJ, Morrison J, Brautbar C, Jacob CO (1998) Synergistic effect between IL-10 and bcl-2 genotypes in determining susceptibility to systemic lupus erythematosus. Arthritis Rheum 41:596–602Google Scholar
  29. Pullmann R Jr, Lukac J, Skerenova M, Rovensky J, Hybenova J, Melus V, Celec S, Pullmann R, Hyrdel R (1999) Cytotoxic T lymphocyte antigen 4 (CTLA-4) dimorphism in patients with systemic lupus erythematosus. Clin Exp Rheumatol 17:725–729Google Scholar
  30. Quintero-del-Rio AI, Kelly JA, Kilpatrick J, James JA, Harley JB (2002) The genetics of systemic lupus erythematosus stratified by renal disease: linkage at 10q22.3 (SLEN1), 2q34-35 (SLEN2), and 11p15.6 (SLEN3). Genes Immun (Suppl 1):S57–62Google Scholar
  31. Quintero-del-Rio AI, Kelly JA, Garriott CP, Hutchings DC, Frank SG, Aston CE, Harley JB (2004) SLEN2 (2q34-35) and SLEN1 (10q22.3) replication in systemic lupus erythematosus stratified by nephritis. Am J Hum Genet 75:346–348CrossRefGoogle Scholar
  32. Takeuchi F, Kawasugi K, Nabeta H, Mori M, Tanimoto K (2003) CTLA-4 dimorphisms in Japanese patients with systemic lupus erythematosus. Clin Exp Rheumatol 21:527–528Google Scholar
  33. Torres B, Aguilar F, Franco E, Sanchez E, Sanchez-Roman J, Alonso JJ, Nunez-Roldan A, Martin J, Francisca Gonzalez-Escribano M (2004) Association of the CT60 marker of the CTLA4 gene with systemic lupus erythematosus. Arthritis Rheum 50:2211–2215CrossRefGoogle Scholar
  34. Ueda H, Howson JM, Esposito L, Heward J, Snook H, Chamberlain G, Rainbow DB, Hunter KM, Smith AN, Di Genova G, Herr MH, Dahlman I, Payne F, Smyth D, Lowe C, Twells RC, Howlett S, Healy B, Nutland S, Rance HE, Everett V, Smink LJ, Lam AC, Cordell HJ, Walker NM, Bordin C, Hulme J, Motzo C, Cucca F, Hess JF, Metzker ML, Rogers J, Gregory S, Allahabadia A, Nithiyananthan R, Tuomilehto-Wolf E, Tuomilehto J, Bingley P, Gillespie KM, Undlien DE, Ronningen KS, Guja C, Ionescu-Tirgoviste C, Savage DA, Maxwell AP, Carson DJ, Patterson CC, Franklyn JA, Clayton DG, Peterson LB, Wicker LS, Todd JA, Gough SC (2003) Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 423:506–511CrossRefPubMedGoogle Scholar
  35. Vyse TJ, Kotzin BL (1996) Genetic basis of systemic lupus erythematosus. Curr Opin Immunol 8:843–851CrossRefPubMedGoogle Scholar
  36. Waterhouse P, Penninger JM, Timms E, Wakeham A, Shahinian A, Lee KP, Thompson CB, Griesser H, Mak TW (1995) Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 270:985–988Google Scholar
  37. Yusuf S, Peto R, Lewis J, Collins R, Sleight P (1985) Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 27:335–371PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2005

Authors and Affiliations

  • Young Ho Lee
    • 1
  • John B. Harley
    • 1
    • 2
    • 3
    • 4
  • Swapan K. Nath
    • 1
    • 2
    • 3
  1. 1.Arthritis and Immunology Research ProgramOklahoma Medical Research FoundationOklahoma CityUSA
  2. 2.Genetic Epidemiology UnitOklahoma Medical Research FoundationOklahoma CityUSA
  3. 3.University of Oklahoma Health Sciences CenterOklahoma CityUSA
  4. 4.US Department of Veterans Affairs Medical CenterOklahoma CityUSA

Personalised recommendations